CRDL Stock Overview A clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Cardiol Therapeutics Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Cardiol Therapeutics Historical stock prices Current Share Price CA$1.35 52 Week High CA$3.12 52 Week Low CA$0.96 Beta 0.66 1 Month Change 0.75% 3 Month Change -32.16% 1 Year Change 27.36% 3 Year Change -19.64% 5 Year Change -56.45% Change since IPO -63.92%
Recent News & Updates
New minor risk - Market cap size Jan 17
President recently bought US$53k worth of stock Dec 19
New major risk - Revenue and earnings growth Nov 18
Cardiol Therapeutics Inc. to Advance CardiolRx into A Late-Stage Trial in Patients with Recurrent Pericarditis Oct 22 Cardiol Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $13.5 million. Oct 10
Cardiol Therapeutics Inc. has filed a Follow-on Equity Offering. See more updates
New minor risk - Market cap size Jan 17
President recently bought US$53k worth of stock Dec 19
New major risk - Revenue and earnings growth Nov 18
Cardiol Therapeutics Inc. to Advance CardiolRx into A Late-Stage Trial in Patients with Recurrent Pericarditis Oct 22 Cardiol Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $13.5 million. Oct 10
Cardiol Therapeutics Inc. has filed a Follow-on Equity Offering.
Cardiol Therapeutics Inc. Achieves Target Patient Enrollment in its Phase II Archer Trial Investigating CardiolRxTM for Acute Myocarditis Sep 24
Cardiol Therapeutics Announces Completion of the Maveric Phase II Study in Recurrent Pericarditis with Results to Be Presented At the American Heart Association Scientific Sessions 2024 Sep 10
President recently bought US$101k worth of stock Jun 25
Cardiol Therapeutics Inc., Annual General Meeting, Jul 26, 2024 Apr 20
Cardiol Therapeutics Inc. Announces It Has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis Jan 10
Cardiol Therapeutics Inc. Announces Massachusetts General Hospital as the 8th Major Medical Centre Participating in MAvERIC-Pilot Dec 07
New minor risk - Shareholder dilution Nov 19
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Oct 24
Cardiol Therapeutics Inc. Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in Model of Heart Failure with Preserved Ejection Fraction Oct 11
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in Archer, A Phase II Trial of Cardiolrx™ for the Treatment of Acute Myocarditis Sep 20
High number of new and inexperienced directors Aug 10
Cardiol Therapeutics Inc., Annual General Meeting, Jun 28, 2023 May 19
Cardiol Therapeutics Inc. Announces First Patient Enrolled in Phase II Study Evaluating Cardiolrx for the Treatment of Recurrent Pericarditis Jan 18
Cardiol Therapeutics Inc. Announces the Initiation of a Phase II Open-Label Pilot Study (NCT05494788), to Investigate the Tolerance, Safety, and Efficacy of CardiolRx in Patients with Recurrent Pericarditis Dec 13
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Nov 16
Cardiol Therapeutics Inc. Announces Study Results Demonstrating Protective Effects of Cardiolrx in A Model of Acute Pericarditis Nov 08
Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases Oct 27
Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating Cardiolrx Inhibits Oct 04
Cardiol Therapeutics Inc. Announces First Patient Enrolled in Archer, A Phase II Clinical Trial of Cardiolrx(TM) for Treatment of Acute Myocarditis Aug 04
Cardiol Therapeutics Inc. Announces Board Appointments May 20
Cardiol Therapeutics Announces FDA Investigational New Drug Application Authorization for Multicenter Phase II Open-Label Pilot Study of Cardiolrx for Recurrent Pericarditis May 18
Cardiol Therapeutics Inc., Annual General Meeting, Jun 28, 2022 Apr 19
Cardiol Therapeutics Inc. Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments in Lancer Trial Mar 03
Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (Ind) Application for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis Aug 26
Cardiol Therapeutics Common Shares Class A Deleted from Other OTC Aug 11
Cardiol Therapeutics Inc. has completed a Composite Units Offering in the amount of CAD 22.0032 million. May 13
Cardiol Therapeutics Announces First Patient Enrolled in Lancer, A Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with Covid-19 Apr 29
Cardiol Therapeutics Inc Announces Formation of Data Safety Monitoring and Clinical Endpoint Committees for Phase Ii/Iii Outcomes Trial in High-Risk Patients Hospitalized with Covid-19 Jan 22
Cardiol Therapeutics Appoints Worldwide Clinical Trials as CRO for the Company's Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with Covid-19 Dec 18
U.S. Food and Drug Administration Approves Cardiol Therapeutics Inc.'S Investigational New Drug Application to Commence A Phase II/III of CardiolRx Sep 26 Shareholder Returns CRDL US Pharmaceuticals US Market 7D -4.3% 1.2% -0.3% 1Y 27.4% 1.1% 20.4%
See full shareholder returns
Return vs Market: CRDL exceeded the US Market which returned 22% over the past year.
Price Volatility Is CRDL's price volatile compared to industry and market? CRDL volatility CRDL Average Weekly Movement 8.5% Pharmaceuticals Industry Average Movement 10.4% Market Average Movement 6.0% 10% most volatile stocks in US Market 18.5% 10% least volatile stocks in US Market 3.0%
Stable Share Price: CRDL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CRDL's weekly volatility (8%) has been stable over the past year.
About the Company Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure.
Show more Cardiol Therapeutics Inc. Fundamentals Summary How do Cardiol Therapeutics's earnings and revenue compare to its market cap? CRDL fundamental statistics Market cap US$118.00m Earnings (TTM ) -US$25.30m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CRDL income statement (TTM ) Revenue CA$0 Cost of Revenue CA$0 Gross Profit CA$0 Other Expenses CA$36.14m Earnings -CA$36.14m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/07 05:10 End of Day Share Price 2025/02/07 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Cardiol Therapeutics Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Edward Nash Canaccord Genuity Charles Duncan Cantor Fitzgerald & Co. Christian Orquera First Berlin Equity Research GmbH
Show 4 more analysts 
